The 15 Most-Watched Biotech Stocks

People watch stocks for different reasons -- they're waiting for a dip in price, watching for a specific catalyst, gathering all the news and information that might affect stocks they already own, or considering a sell. Regardless of their motivation, we can better understand market sentiment by seeing who's watching what. With the Fool's free My Watchlist service, we have tens of thousands of people telling us the businesses that have, for whatever reason, piqued their interest.

The most-watched biotech stock is ...
Looking at the aggregate data, we see that Gilead Sciences (Nasdaq: GILD  ) is above the rest in terms of watch interest, the percentage of people keeping an eye on biotech stocks in general who are specifically watching each company. And for good reason. As CAPS Member CarolinaMatt wrote last week:

Yes I get it. This company is no longer the high-flying early stage pharma star with a everything under patent and profits growing as fast as it can ramp distribution.

But this is no old super-slow moving huge pharma company either. Pricing is at a 2011 P/E of about 9X which suggests maturity and minimal EPS growth. But this company is still projected to grow EPS at 15ish% over the next 3-5 years. Even if they fall short and come in at more like 10-11% EPS gains it is a bargain in the drug space

Here are the rest of the top 15 most-watched companies in the industry with their watch interest along with the stocks' CAPS rating to show the sentiment of our investing community.

 

Company

Market Cap (millions)

CAPS Rating (out of 5)

Watch Interest

1

Gilead Sciences

$33,828

****

25.5%

2

Exelixis (Nasdaq: EXEL  )

$1,451

****

9.3%

3

Amgen

$49,495

***

2.8%

4

Dendreon (Nasdaq: DNDN  )

$5,444

**

2.6%

5

ImmunoGen

$611

***

2.4%

6

Maxygen

$157

****

2.2%

7

MannKind (Nasdaq: MNKD  )

$491

**

2.0%

8

PDL BioPharma (Nasdaq: PDLI  )

$827

****

1.8%

9

Celgene

$26,639

****

1.8%

10

Geron (Nasdaq: GERN  )

$661

***

1.7%

11

Vertex Pharmaceuticals

$9,728

***

1.5%

12

Arena Pharmaceuticals (Nasdaq: ARNA  )

$184

**

1.5%

13

Human Genome Sciences

$5,165

**

1.4%

14

Orexigen Therapeutics

$138

**

1.4%

15

Biogen Idec

$17,626

***

1.1%

Source: Motley Fool, Motley Fool CAPS.

Whether you're keeping an eye on the industry stalwarts such as Gilead Sciences or are watching an up-and-comer such as Arena Pharmaceuticals, it pays to watch. We can help you keep tabs on your companies with My Watchlist, our free, personalized stock tracking service. Click here to start now.

Dan Dzombak's musings and articles he finds interesting can be found on his Twitter account: @DanDzombak.

Exelixis, ImmunoGen, and Vertex Pharmaceuticals are Motley Fool Rule Breakers selections. Gilead Sciences is a Motley Fool Stock Advisor recommendation. The Fool owns shares of Exelixis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (8)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1469711, ~/Articles/ArticleHandler.aspx, 10/2/2014 6:49:39 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement